-
公开(公告)号：US20240325561A1
公开(公告)日：2024-10-03
申请号：US18740431
申请日：2024-06-11
申请人： Seagen Inc.
发明人： Robert LYON , Patrick BURKE , Joshua HUNTER
CPC分类号： A61K47/6817 , A61K47/549 , A61K47/60 , A61K47/6819 , A61K47/6851 , A61K47/6883 , A61K47/6885 , C07K16/28 , C07K16/2878 , A61K2039/505 , C07K2317/94
摘要： The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.
-
公开(公告)号：US12071480B2
公开(公告)日：2024-08-27
申请号：US17505911
申请日：2021-10-20
申请人： Seagen Inc.
发明人： Shyra Gardai , Matthew Levengood , Vivian Trang , Lori Westendorf , Christopher Carosino , Che Leung-Law , Michael Feldhaus
CPC分类号： C07K16/2803 , A61P35/00 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2319/50 , C07K2319/73
摘要： Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
-
公开(公告)号：US20240252672A1
公开(公告)日：2024-08-01
申请号：US18495728
申请日：2023-10-26
申请人： Seagen Inc.
发明人： Scott JEFFREY
CPC分类号： A61K47/6867 , A61K38/07 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6861 , A61K47/6889 , Y02A50/30
摘要： Ligand Drug conjugate compounds comprising a β-glucuronide-based linker and methods of using such compounds are provided.
-
公开(公告)号：US20240247030A1
公开(公告)日：2024-07-25
申请号：US18509211
申请日：2023-11-14
申请人： Seagen Inc.
IPC分类号： C07K7/06 , A61K45/06 , A61K47/54 , A61K47/64 , A61K47/68 , C07H15/26 , C07K5/117 , C07K7/02 , C07K16/28
CPC分类号： C07K7/06 , A61K45/06 , A61K47/545 , A61K47/6415 , A61K47/6817 , A61K47/6849 , A61K47/6889 , C07H15/26 , C07K5/1024 , C07K7/02 , C07K16/2875 , C07K16/2878 , C07K16/2881 , C07K2317/24
摘要： Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action.
Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.-
公开(公告)号：US20240216420A1
公开(公告)日：2024-07-04
申请号：US18500858
申请日：2023-11-02
申请人： Seagen Inc.
摘要： Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
-
公开(公告)号：US20240158484A1
公开(公告)日：2024-05-16
申请号：US18487900
申请日：2023-10-16
申请人： Seagen Inc.
发明人： Matt ONSUM , Hailing LU , Zejing WANG
CPC分类号： C07K16/18 , A61K47/6817 , A61K47/6843 , A61P35/00 , A61P35/04 , C07K16/2818 , A61K2039/505
摘要： Methods for using anti-LIV1 antibodies and antibody-drug conjugates, including anti-LIV1 antibody-drug conjugates, to inhibit proliferation of a cell, as well as for the treatment of cancers, such as, e.g., prostate cancer and melanoma, are provided.
-
公开(公告)号：US20240075135A1
公开(公告)日：2024-03-07
申请号：US18471051
申请日：2023-09-20
申请人： Seagen Inc.
发明人： Shyra Gardai , Che-Leung Law , Stanford Peng , Jing Yang , Haley Neff-LaFord , Thomas John Manley
IPC分类号： A61K39/395 , A61M25/00 , C07K16/28
CPC分类号： A61K39/3955 , A61K39/395 , A61K39/39558 , A61M25/0012 , A61M25/0017 , A61M25/002 , C07K16/2878 , A61K2039/505 , C07K2317/41 , C07K2317/732 , C07K2317/92
摘要： This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
-
公开(公告)号：US20240033369A1
公开(公告)日：2024-02-01
申请号：US18172123
申请日：2023-02-21
申请人： Seagen Inc.
发明人： Sharsti SANDALL , Lori WESTENDORF , Timothy LEWIS
CPC分类号： A61K47/6811 , A61K47/6843 , A61P35/00 , C07K2317/565 , C07K2317/24 , C07K2317/52 , C07K16/2896
摘要： Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.
-
公开(公告)号：US20230330241A1
公开(公告)日：2023-10-19
申请号：US18171208
申请日：2023-02-17
申请人： Seagen Inc.
发明人： Emily STEVENS , Hong LI , William HANLEY , Phillip GARFIN , Shawna HENGEL
CPC分类号： A61K47/6801 , A61P35/00 , A61K9/0019 , C07K16/2818 , C07K16/2827
摘要： Methods for using anti-LIV1 antibodies and antibody-drug conjugates, including anti-LIV1 antibody-drug conjugates, to inhibit proliferation of a cell, such as a LIV1-expressing cell, as well as for the treatment of cancers, such as, e.g., LIV1-associated solid tumors and breast cancer (e.g., locally advanced or metastatic breast cancer), are provided.
-
公开(公告)号：US20230287322A1
公开(公告)日：2023-09-14
申请号：US18016648
申请日：2021-07-27
申请人： Seagen Inc.
CPC分类号： C12M29/04 , C12P21/02 , C12M47/10 , C12M29/10 , B01D61/149 , B01D69/02 , B01D2315/10 , B01D2311/04 , B01D61/147 , B01D61/145 , B01D2325/02834 , B01D2325/34
摘要： Provided herein are methods and systems for production (e.g., batch production) of a polypeptide product via cell culture. In some embodiments, the methods and systems use a first bioreactor (e.g., for cell culturing), an alternating tangential flow (ATF) microfilter (e.g., for removing a polypeptide product and culture medium from the cell culture while retaining cells), a second bioreactor (e.g., for concentrating the product), and an ATF ultrafilter (e.g., for retaining product in the second bioreactor and allowing culture medium to exit).
-
-
-
-
-
-
-
-
-
搜索结果
194 条记录 (耗时 0.028 秒)
